Physician profile
Bilal Dar
NPI 1174910392
$10,236.27
in general payments reported to CMS, 2019-2025
32 companies · $1,395 in 2025
The $1,395 reported for 2025 was more than what 95% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,808 · 2020: $759 · 2021: $1,091 · 2022: $2,239 · 2023: $1,636 · 2024: $1,308 · 2025: $1,395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,553 · Travel and Lodging: $787.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,552.74 |
| Travel and Lodging | $786.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,674.00 | 2020-2025 | Vercise, Wavewriter Alpha Prime 16, Clinical Trial Product |
| Abbott Laboratories | $2,477.02 | 2019-2024 | Proclaim, Eterna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $975.43 | 2020-2024 | Relistor |
| Medtronic, INC. | $567.82 | 2021-2025 | Intellis Adaptivestim, Swiftset, Inceptiv |
| Nevro Corp. | $527.10 | 2019-2023 | Senza |
| Medtronic USA, INC. | $355.02 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $339.89 | 2021-2024 | Belbuca, Xtampza |
| Saluda Medical Americas, INC. | $299.01 | 2024 | Evoke |
| Grt US Holding, INC. | $297.01 | 2020-2021 | |
| Abbvie INC. | $231.41 | 2021-2024 | |
| Painteq LLC | $203.50 | 2024 | Painteq |
| Scilex Pharmaceuticals INC. | $189.10 | 2020-2024 | Ztlido |
| Lundbeck LLC | $175.44 | 2022-2024 | Vyepti |
| Hikma Pharmaceuticals USA | $134.97 | 2022-2024 | Kloxxado |
| Biohaven Pharmaceutical Holding Company LTD. | $119.52 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $113.81 | 2023-2024 | |
| Biotronik Nro, INC. | $110.24 | 2025 | Prospera |
| Redhill Biopharma INC. | $61.92 | 2021 | |
| Spr Therapeutics, INC | $45.00 | 2021 | |
| Depuy Synthes Sales INC. | $41.69 | 2021-2022 | |
| Biodelivery Sciences International, INC. | $39.86 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $38.83 | 2022-2023 | Ajovy |
| Globus Medical, INC. | $36.59 | 2022 | |
| Trice Medical, INC. | $28.11 | 2023 | |
| Azurity Pharmaceuticals, INC. | $26.82 | 2023-2024 | Horizant, Horizant |
| Vertos Medical, INC. | $25.70 | 2023 | Mild Device Kit |
| Amgen INC. | $23.83 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $22.84 | 2023 | Iovera, Zilretta |
| Lilly USA, LLC | $20.68 | 2022 | |
| Protega Pharmaceutials INC | $14.00 | 2023 | Roxybond |
| Averitas Pharma INC. | $13.29 | 2023 | Qutenza |
| Epimed International, INC | $6.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bilal Dar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.